Organization
Shanxi Provincial Cancer Hospital, Taiyuan, China
2 abstracts
Abstract
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.Org: National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Internal Medicine-Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Shanxi Provincial Cancer Hospital, Taiyuan, China,
Abstract
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.Org: Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Linyi Cancer Hospital, Linyi, China, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China,